Malignancies and Aortic Stenosis: Is TAVR Warranted?

This meta-analysis tells us that patients with active malignancies and severe aortic stenosis have a good evolution after transcatheter aortic valve replacement (TAVR), except for a higher rate of pacemaker implantation in the general population.

Enfermedades malignas y estenosis aórtica ¿Se justifica el TAVI?

These patients must not be limited to respite care only, at least as far as aortic stenosis is concerned.

Short-term results after TAVR have the same efficacy and safety that in cancer-free patients. In the long term, malignancy stage does make a difference.

All initial and paradigmatic studies on TAVR systematically excluded patients with any type of malignancy.

Advanced cancer was defined as a stage greater than T2 for the primary tumor, N1 for lymph nodes, and/or M1 for metastases. Researchers also considered whether the malignancy was refractory, relapsing, or recurrent. Mortality 1 year after TAVR was more than twofold higher among patients with advanced disease stages compared with patients with limited disease stages.


Read also: Myocardial Fibrosis in Severe Aortic Stenosis: A Matter of Sex?


These huge differences in survival at 1 year should be taken into account when making decisions about conducting TAVR on a given patient, but they do not mean that we should routinely exclude the procedure as an alternative for all cancer patients.

Recently published in Open Heart, this meta-analysis pooled 3 studies, with a total of 5162 patients who underwent TAVR. Of these, 7.1% had an active cancer. The most common cancer types were gastrointestinal (22.6%), prostate (18.4%), hematological (17.1%), and breast (14.4%).

After 30 days of follow-up, all-cause mortality was similar among patients with and without active cancer (risk ratio [RR]: 0.92; 95% confidence interval [CI]: 0.53-1.59). These differences became apparent only at 1 year and were driven by advanced-stage patients.


Read also: In Search of the Optimal Depth for Self-Expandable Valves.


The only safety endpoint that was higher among patients with cancer was the need for a permanent pacemaker (RR: 1.29; 95% CI: 1.06-1.58). Frequently used drugs such as methotrexate, 5-fluorouracil, and cisplatin are associated with conduction disorders and might explain the higher pacemaker implantation rates.

Descargar (PDF, Unknown)

Original Title: Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis.

Reference: Bendary A et al. Open Heart. 2020;7:e001131.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

*

Top